INTRODUCTION: Cardiac implantable electronic device (CIED) infections are potentially preventable complications associated with high morbidity, mortality, and cost. A recently developed bio-absorbable antibacterial envelope (TYRX™-A) might prevent CIED infections in high-risk subjects. However, data regarding safety and efficacy have not been published. METHODS AND RESULTS: In a single-center retrospective cohort study, we compared the prevalence of CIED infections among subjects with ≥2 risk factors treated with the TYRX™-A envelope (N = 135), the nonabsorbable TYRX™ envelope (N = 353), and controls who did not receive an envelope (N = 636). Infection was ascertained by individual chart review. The mean (95% confidence interval) number of risk factors was 3.08 (2.84-3.32) for TYRX™-A, 3.20 (3.07-3.34) for TYRX™, and 3.09 (2.99-3.20) for controls, P = 0.3. After a minimum 300 days follow-up, the prevalence of CIED infection was 0 (0%) for TYRX™-A, 1 (0.3%) for TYRX™, and 20 (3.1%) for controls (P = 1 for TYRX™-A vs. TYRX™, P = 0.03 for TYRX™-A vs. controls, and P = 0.002 for TYRX™ vs. controls). In a propensity score-matched cohort of 316 recipients of either envelope and 316 controls, the prevalence of infection was 0 (0%) and 9 (2.8%), respectively, P = 0.004. When limited to 122 TYRX™-A recipients and 122 propensity-matched controls, the prevalence of CIED infections was 0 (0%) and 5 (4.1%), respectively, P = 0.024. CONCLUSIONS: Among high-risk subjects, the TYRX™-A bio-absorbable envelope was associated with a very low prevalence of CIED related infections that was comparable to that seen with the nonabsorbable envelope.
INTRODUCTION: Cardiac implantable electronic device (CIED) infections are potentially preventable complications associated with high morbidity, mortality, and cost. A recently developed bio-absorbable antibacterial envelope (TYRX™-A) might prevent CIED infections in high-risk subjects. However, data regarding safety and efficacy have not been published. METHODS AND RESULTS: In a single-center retrospective cohort study, we compared the prevalence of CIED infections among subjects with ≥2 risk factors treated with the TYRX™-A envelope (N = 135), the nonabsorbable TYRX™ envelope (N = 353), and controls who did not receive an envelope (N = 636). Infection was ascertained by individual chart review. The mean (95% confidence interval) number of risk factors was 3.08 (2.84-3.32) for TYRX™-A, 3.20 (3.07-3.34) for TYRX™, and 3.09 (2.99-3.20) for controls, P = 0.3. After a minimum 300 days follow-up, the prevalence of CIED infection was 0 (0%) for TYRX™-A, 1 (0.3%) for TYRX™, and 20 (3.1%) for controls (P = 1 for TYRX™-A vs. TYRX™, P = 0.03 for TYRX™-A vs. controls, and P = 0.002 for TYRX™ vs. controls). In a propensity score-matched cohort of 316 recipients of either envelope and 316 controls, the prevalence of infection was 0 (0%) and 9 (2.8%), respectively, P = 0.004. When limited to 122 TYRX™-A recipients and 122 propensity-matched controls, the prevalence of CIED infections was 0 (0%) and 5 (4.1%), respectively, P = 0.024. CONCLUSIONS: Among high-risk subjects, the TYRX™-A bio-absorbable envelope was associated with a very low prevalence of CIED related infections that was comparable to that seen with the nonabsorbable envelope.
Authors: A Da Costa; H Lelièvre; G Kirkorian; M Célard; P Chevalier; F Vandenesch; J Etienne; P Touboul Journal: Circulation Date: 1998-05-12 Impact factor: 29.690
Authors: Mihály K de Bie; Johannes B van Rees; J Thijssen; C Jan Willem Borleffs; Serge A Trines; Suzanne C Cannegieter; Martin J Schalij; Lieselot van Erven Journal: Heart Rhythm Date: 2011-11-03 Impact factor: 6.343
Authors: Suneet Mittal; Richard E Shaw; Kimberly Michel; Rachel Palekar; Aysha Arshad; Dan Musat; Mark Preminger; Tina Sichrovsky; Jonathan S Steinberg Journal: Heart Rhythm Date: 2013-12-10 Impact factor: 6.343
Authors: Arnold J Greenspon; Jasmine D Patel; Edmund Lau; Jorge A Ochoa; Daniel R Frisch; Reginald T Ho; Behzad B Pavri; Steven M Kurtz Journal: J Am Coll Cardiol Date: 2011-08-30 Impact factor: 24.094
Authors: Muhammad R Sohail; Salwa Hussain; Katherine Y Le; Chadi Dib; Christine M Lohse; Paul A Friedman; David L Hayes; Daniel Z Uslan; Walter R Wilson; James M Steckelberg; Larry M Baddour Journal: J Interv Card Electrophysiol Date: 2011-03-02 Impact factor: 1.900
Authors: Heather Bloom; Brian Heeke; Angel Leon; Fernando Mera; David Delurgio; John Beshai; Jonathan Langberg Journal: Pacing Clin Electrophysiol Date: 2006-02 Impact factor: 1.976
Authors: M Rizwan Sohail; Charles A Henrikson; Mary Jo Braid-Forbes; Kevin F Forbes; Daniel J Lerner Journal: Am J Cardiol Date: 2013-08-22 Impact factor: 2.778